1. Scrip
  2. >>Focus On Asia
  3. >>China

RNA-Based Therapies Back In Spotlight As Chinese Biotechs Raise $366m

 
• By Dexter Jie Yan

Four Chinese RNA technology developers, including Rona Therapeutics and METiS Pharmaceuticals, have bagged the most proceeds in recent financing rounds in the country backed by venture capital and private equity funds.

fund raising
Investors reignited interest in Chinese biotechs focused on nucleic acid therapeutics • Source: Alamy

Venture capital and private equity investors have recently reignited their interest in Chinese biotechs focused on nucleic acid platforms such as messenger RNA-based therapeutics, with four biotechs in this field recently raising a combined $366m.

Shanghai-based Rona Therapeutics, an RNA therapeutics platform company, on 7 April closed a series A funding to raise $33m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.